# US 2019/0240311 A1 · Pestivirus marker vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0240311 A1
- Document ID: US20190240311A1
- Status: Published application
- Kind: A1
- Application number: 16/066,218
- Filed: 2016-12-23
- Published: 2019-08-08
- Earliest claimed: 2015-12-30
- Assignees: Intervet Inc.
- Applicants: Intervet Inc.
- Inventors: Ilona REIMANN; Patricia KONIG; Martin BEER
- Web page: https://patentgrep.com/patent/US20190240311A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/04: Inactivation or attenuation; Producing viral sub-units
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/575: {humoral response}
- C07K 2319/00: Fusion polypeptide
- C12N 2770/24321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/24322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24362: by genetic engineering
- C12N 2770/24371: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a mutant Pestivirus comprising a chimeric Erns gene, which provides the mutant Pestivirus with the capacity to evade serologic detection, but maintains good vaccine properties, and viral replication.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

A mutant Pestivirus comprising a genome wherein an Erns gene is mutated, wherein said mutated Erns gene is a chimeric Erns gene, wherein said chimeric Erns gene comprises a 5′ part and a 3′ part, wherein said 5′ part comprises 60-95% of the chimeric Erns gene, wherein said 3′ part comprises the remainder of the chimeric Erns gene, wherein said 5′ part comprises the corresponding part of an Erns gene from a Pestivirus that is genetically distant from the mutant Pestivirus, and wherein said 3′ part comprises the corresponding part of an Erns gene from a Pestivirus that is genetically close to the mutant Pestivirus.

### Claim 23 (depends on 22)

The mutant Pestivirus of claim 22, wherein the mutant Pestivirus is a Pestivirus selected from the group consisting of: bovine viral diarrhoea virus (BVDV), classical swine fever virus (CSFV), and border disease virus.

### Claim 24 (depends on 22)

The mutant Pestivirus of claim 22, wherein the Erns gene from a Pestivirus that is genetically distant from the mutant Pestivirus, is an Erns gene from a Pestivirus selected from the group consisting of: Antelope Pestivirus, Bungowannah virus, Norway rat Pestivirus, atypical porcine Pestivirus (APPV), and Rhinolophus affinis Pestivirus.

### Claim 25 (depends on 22)

The mutant Pestivirus of claim 22, wherein the Erns gene from a Pestivirus that is genetically close from the mutant Pestivirus, is an Erns gene from a Pestivirus selected from the group consisting of: bovine viral diarrhoea virus type 1 (BVDV-1), bovine viral diarrhoea virus type 2 (BVDV-2), CSFV, border disease virus, Reindeer Pestivirus, Giraffe Pestivirus, and HoBi Pestivirus.

### Claim 26 (depends on 22)

The mutant Pestivirus of claim 22, wherein the mutant Pestivirus is an attenuated Pestivirus.

### Claim 27 (depends on 26)

The mutant Pestivirus of claim 26, wherein the attenuated Pestivirus comprises a genome wherein the Npro gene is mutated.

### Claim 28 (depends on 22)

The mutant Pestivirus of claim 22, wherein the mutant Pestivirus is a bovine viral diarrhoea virus (BVDV), wherein the BVDV is of the cytopathogenic biotype.

### Claim 29 (depends on 22)

A method for the construction of the mutant Pestivirus of claim 22, wherein said method comprises mutating the Erns gene in a Pestivirus genome into a chimeric Erns gene as defined in claim 22.

### Claim 30 (depends on 22)

A host cell comprising the mutant Pestivirus of claim 22.

### Claim 31 (depends on 29)

A host cell constructed by the method of claim 29.

### Claim 32 (depends on 22)

A vaccine for animals comprising the mutant Pestivirus according to claim 22 and a pharmaceutically acceptable carrier.

### Claim 33 (depends on 30)

A vaccine for animals comprising the host cell of claim 30 and a pharmaceutically acceptable carrier.

### Claim 34 (depends on 31)

A vaccine for animals comprising the host cell of claim 31 and a pharmaceutically acceptable carrier.

### Claim 35 (depends on 22)

A method for the preparation of a vaccine for animals comprising the mutant Pestivirus according to claim 22 and a pharmaceutically acceptable carrier, wherein said method comprises:
a. infecting a culture of host cells with said mutant Pestivirus of claim 22,
b. incubating said infected culture of host cells,
c. harvesting said culture of host cells or a part thereof, and
d. admixing the culture of host cells or the part thereof, with a pharmaceutically acceptable carrier.

### Claim 36 (depends on 22)

The mutant Pestivirus of claim 22 for use in a vaccine for animals.

### Claim 37 (depends on 30)

The host cell of claim 30 for use in a vaccine for animals.

### Claim 38 (depends on 31)

The host cell of claim 31 for use in a vaccine for animals.

### Claim 39 (depends on 32)

A method for the prevention or reduction of an infection by a Pestivirus or of associated signs of disease in animals, wherein said method comprises administering the vaccine of claim 32 to said animals.

### Claim 40 (depends on 32)

A method of vaccinating animals for the prevention or reduction of an infection by a Pestivirus or of associated signs of disease, wherein said method comprises administering the vaccine of claim 32 to said animals.

### Claim 41 (depends on 32)

A method for differentiating animals vaccinated with the vaccine according to claim 32, from animals infected with a Pestivirus other than a mutant Pestivirus comprised in the vaccine, the method comprising the use of an antibody against an Erns protein, which antibody does not bind specifically with the chimeric Erns protein expressed by a mutant Pestivirus that is comprised in the vaccine.

### Claim 42 (depends on 41)

A method of claim 41, wherein said antibody binds specifically with an Erns protein from a Pestivirus selected from the group consisting of: BVDV-1, BVDV-2, CSFV, and border disease virus.

### Claim 43 (depends on 32)

A method for diagnosing an animal that was vaccinated with the vaccine according to claim 32, for an infection with a Pestivirus other than a mutant Pestivirus comprised in the vaccine, the method comprising the steps of:
a. obtaining a sample from said vaccinated animal, and
b. testing said sample for the presence of an antibody against a Pestivirus other than a mutant Pestivirus comprised in the vaccine, by using a mutant Pestivirus comprised in the vaccine, or a chimeric Erns protein as expressed by the mutant Pestivirus comprised in the vaccine, in an immuno-assay.

### Claim 44 (depends on 22)

A diagnostic test kit comprising the mutant Pestivirus according to claim 22, or a chimeric Erns protein as expressed by the mutant Pestivirus.

### Claim 45 (depends on 32)

A method for controlling an infection with a Pestivirus in a population of animals from the order of the Artiodactyla, comprising the use of the vaccine according to claim 32.

### Claim 46 (depends on 44)

A method for controlling an infection with a Pestivirus in a population of animals from the order of the Artiodactyla, comprising the use of the diagnostic test kit according to claim 44.
